Aktie A2DNCF THE GREATER CANNABIS COMPANY, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen The Greater Cannabis Company, Inc. Other OTC

Aktien

A2DNCF

US3916571033

GCAN

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
The Greater Cannabis Company, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
GCANRx Announces Completion of Preclinical Study for Neuropsychiatric Cannabinoid Therapy
The Greater Cannabis Company, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
GCANRx Featured in American Journal of Endocannabinoid Medicine
The Greater Cannabis Company, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Nanocap Potential Breakout Watchlist (EPAZ, GCAN, IQST, ONCR)
GCANRx Announces Approval of Phase II Clinical Trial to Treat Autism Related Spectrum Disorders
The Greater Cannabis Company, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
GREATER CANNABIS COMPANY, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)
The Greater Cannabis Company, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
The Greater Cannabis Company, Inc. Auditor Raises 'Going Concern' Doubt
Greater Cannabis : Change in Certifying Accountants - Form 8-K
GREATER CANNABIS COMPANY, INC. : Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits (form 8-K)
GREATER CANNABIS COMPANY, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
The Greater Cannabis Company, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
GCANRx Announces Submission of Phase 2 Clinical Trial Application to Treat Autism Related Spectrum Disorders
GCANRx Announces Submission of Phase 2 Clinical Trial Application to Treat Autism Related Spectrum Disorders
Greater Cannabis Company, Inc. Announces Submission of Phase 2 Clinical Trial Application to Treat Autism Related Spectrum Disorders
GREATER CANNABIS COMPANY, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
The Greater Cannabis Company, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2DNCF Aktie
  4. A2DNCF Aktie
  5. Nachrichten The Greater Cannabis Company, Inc.
  6. Andere Sprachen